The potential to improve cancer care in China is clear, the journey to that destination is not. Here, we bring together a group of experienced RWE leaders, thinkers, and “doers” for an interactive, friendly, and informative discussion about the unique attributes of oncology care in China: diverse patient journeys, integration with traditional medicines, immature EHR integration across institutions, and the rapidly evolving regulatory and reimbursement environment.
Join us for what promises to be an interesting thoughtful discussion regarding this fast-growing opportunity for market development and clinical impact.
Learning Objectives:
- Understanding the unique attributes of oncology care in China- the challenges and opportunities for RWE and outcomes researchers.
- Ways to effectively manage Chinese data and privacy regulations to support global pharma RWE research and market access teams.
Click here for additional information and registration details.
Related Content
Evidence Matters 2022
Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.
Achieving Consensus When Everyone is an Expert, but No One Agrees
Join experts from PHAR, Novartis, and Bausch Health for a discussion around the Delphi panels and how the results are used.
Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to Achieve Optimal Access
Experts will present opportunities for using agile platforms and fit-for-purpose engagement models that can drive an iterative approach to obtaining payer insights and developing impactful evidence generation strategies.